KYMR Kymera Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815442 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY133.8%
TTM net income YoY-18.4%
TTM EPS YoY-1.1%
Revenue 3-yr CAGR29.7%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-396.0%
Net margin-341.8%
FCF margin-282.6%
EBITDA margin-388.9%
Returns
ROE-27.3%
ROA-24.4%
ROIC (approx.)-30.8%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets8.6%
Debt / equity0.00x
Current ratio11.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $39.21M | $47.07M |
| Cost of revenue | $39.21M | $47.07M |
| Gross profit | $0 | $0 |
| R&D expense | $316.57M | $240.25M |
| SG&A expense | $68.19M | $63.53M |
| Operating income | -$349.40M | -$261.63M |
| Pretax income | -$311.35M | — |
| Income tax | $0 | — |
| Net income | -$311.35M | -$223.86M |
| EBITDA | -$341.09M | -$254.26M |
| EPS (basic) | -3.69 | -2.98 |
| EPS (diluted) | -3.69 | -2.98 |
| Weighted avg. shares (diluted) | 84.49M | 75.04M |
| Balance sheet | ||
| Cash & equivalents | $357.01M | $120.26M |
| Short-term investments | $491.26M | $368.49M |
| Receivables | $0 | $0 |
| Current assets | $871.21M | $510.27M |
| PP&E, net | $43.17M | $50.46M |
| Total assets | $1.74B | $978.03M |
| Current liabilities | $83.21M | $67.77M |
| Total liabilities | $163.15M | $142.42M |
| Shareholders' equity | $1.58B | $835.62M |
| Shares outstanding | 81.32M | 64.89M |
| Cash flow statement | ||
| Operating cash flow | -$232.89M | -$194.50M |
| Capital expenditure | $1.45M | $12.84M |
| Free cash flow | -$234.34M | -$207.34M |
| Investing cash flow | -$521.06M | -$404.08M |
| Financing cash flow | $990.71M | $608.85M |
| Depreciation & amortization | $8.31M | $7.37M |
| Stock-based compensation | $59.90M | $55.01M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.